Mutant op CALR-peptide gebaseerd vaccin bij patiënten met gemuteerd CALR myeloproliferatief neoplasma
Een fase I open-label vaccin op basis van peptiden bij patiënten met myeloproliferatief neoplasma met CALR-mutaties
The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questionnaires, bone marrow biopsies, research lab collection, and standard of care lab draw. This research will be taking place only at The Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Current MPN treatments are geared towards symptom palliation and not on changing the natural course of the disease. Mutations in calreticulin gene (CALR) is the second most common driver mutation in ET and MF patients (30%). All CALR mutations identified to date in MPN patients result in the formation of an altered protein with an identical 36-amino acid sequence in the C-terminus. This altered protein results in a MPN-specific shared neo-antigen. The mutated CALR neoantigen present in patient with MPN represents an ideal antigen for targeted immunotherapy as it is stably and specifically expressed by the malignant cells and is absent in the normal tissues. CALR neoantigen is immunogenic, effector T cells are capable of recognizing this neo-antigen, and hematopoietic cells carrying the mutation can be potently killed by these specific effector T-cells in vitro.
The researchers believe that a mutated-CALR vaccine will enhance mutated-CALR-specific T cell immunity in MPN patients carrying CALR mutations, which in turn would target and eliminate CALR+ malignant cells, thereby leading to improved clinical outcomes in this patient population.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Subjects must be ≥18 years of age at the time of signing the informed consent form.
-
Confirmed diagnosis of chronic phase MPN:
-
Previously treated or relapsed/refectory high risk ET
-
Low to intermediate 1 risk (DIPSS 0-1) PMF or ET-MF
-
Verified mutation in CALR exon 9
-
PS ≤ 2
-
Adequate organ function:
- Absolute neutrophil count ≥ 1000/mm3,
- Platelet count ≥ 50,000/mm3,
- Creatinine ≤ 2.5 mg/dL,
- Total bilirubin ≤ 2 mg/dL, (except in patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL)
- Transaminases < 3 times above the upper limits of the institutional normal.
-
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to starting study medication and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks prior to first dose of vaccine. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy.
-
Ability to understand and the willingness to sign a written informed consent.
-
Ability to adhere to the study visit schedule and all protocol requirements.
-
Subjects receiving cytoreductive therapy with hydroxyurea must be on a stable dose for at least 8 weeks prior to week 1.
Exclusion Criteria:
- Other invasive malignancy in the past 3 years except non-melanoma skin cancer, localized cured prostate cancer and early stage breast cancer on HRT.
- Active autoimmune disease.
- Uncontrolled serious infection.
- Known immunodeficiency.
- Pregnant and breastfeeding women.
- Not willing to use contraception.
- Current use of immunosuppressive medications including steroids.
- Current JAK inhibitor use.
- Current use of IFN (use of anagrelide is permitted).
- Treatment with other experimental drugs within 30 days of week 1.
- Treatment with any MPN directed therapy unless otherwise noted within 5 half-lives of week 1.
- Any significant psychiatric/medical condition per investigators judgment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: CALR mutated
peptide-based vaccine in patients with myeloproliferative neoplasm (myelofibrosis and essential thrombocythemia) with CALR mutations |
ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart. ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants with Dose Limiting Toxicity (DLT)
Tijdsspanne: 32 weeks
|
The Dose Limiting Toxicity (DLT) rate, defined as the proportion of patients with at least 1 grade 3 or higher AE considered to be at least possibly related to the treatment with Poly ICLC and CALR vaccines. |
32 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Adverse Events
Tijdsspanne: Week 32
|
The type, incidence, severity, seriousness, and relatedness of adverse events (AEs) per NCI CTCAE v5.0. |
Week 32
|
|
Number of laboratory abnormalities
Tijdsspanne: Baseline through Week 32
|
Number of observations, severity, and relatedness of clinical laboratory tests (hematology, biochemistry) |
Baseline through Week 32
|
|
Change in Immune Milieu Composite
Tijdsspanne: Baseline through Weeks 55 or 80
|
Changes in the immune milieu (which is a composite of expression of cytokines, presence of antibodies, alterations in number and phenotype of immune cells and induction of vaccine-specific T cell response) due to the vaccines as compared to baseline values. |
Baseline through Weeks 55 or 80
|
|
Change in CALR VAF
Tijdsspanne: Baseline through Weeks 55 or 80
|
The % change in driver mutation burden (CALR VAF) as compared to baseline |
Baseline through Weeks 55 or 80
|
|
Proportion of participants who normalize their platelet number
Tijdsspanne: Week 32 and weeks 55 or 80
|
The proportion of patients who normalize their platelet number and/or achieve platelets less than 600 if started with platelet above 600. |
Week 32 and weeks 55 or 80
|
|
Proportion of participants achieving response
Tijdsspanne: Baseline and Week 32
|
The proportion of patients achieving response or improvement in their disease status by ELN/IWG criteria for the categories: Complete Response; Partial Response; Clinical Improvement and Stable Disease |
Baseline and Week 32
|
|
Myelofibrosis Symptom Assessment Form (MF-SAFv4.0)
Tijdsspanne: Week 32 and weeks 55 or 80
|
The proportion of patients who achieve improvement in quality of life as assessed by the by the Myelofibrosis Symptom Assessment Form. Each of the items are scored 0 to 10, with total score from 0 to 100, with higher score indicating more symptoms. |
Week 32 and weeks 55 or 80
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai
- Studie stoel: Nina Bhardwaj, MD, PhD, Icahn School of Medicine at Mount Sinai
- Studie stoel: Camelia Iancu-Rubin, PhD, Icahn School of Medicine at Mount Sinai
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- GCO 22-1330
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Not determined at this time
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .